CGRP mAb Iv denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for cgrp mab iv are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Limits Quantities of IV CGRP Monoclonal Antibodies — and Why You Can Appeal

Intravenous CGRP monoclonal antibodies are administered on a fixed infusion schedule defined in the FDA-approved prescribing label. Humana's quantity-limit restriction reflects that schedule: the plan will only authorize the number of doses that align with the approved dosing interval over a given period. Denials occur most often when the requested supply does not match the plan's interpretation of the label's dosing interval, or when an administrative mismatch exists between the quantity on the prescription and the quantity Humana's system expects.

This is one of the most straightforwardly winnable appeal types because the correct quantity is a matter of documented clinical record, not clinical judgment.

## Federal Appeal Framework

All appeals of quantity-limit decisions fall under the same federal protections as other coverage denials. Under ACA Section 2719 and its implementing regulations, non-grandfathered plans must provide an internal appeal followed by an independent external review. ERISA Section 503 requires a full-and-fair review for employer-sponsored plans. You generally have approximately 180 days from the denial notice to file an internal appeal, and if that is upheld, you may request external review — typically within four months of the internal denial. An expedited appeal (resolution within 72 hours) is available if a standard timeline would seriously jeopardize your health.

## Concrete Appeal Steps

1. Request the denial letter in writing if you have not already received it. It must state the specific quantity-limit criterion that was applied. 2. Obtain Humana's current published coverage policy for this medication — the policy number and criteria are available on Humana's provider/member portal. 3. Cross-reference the FDA-approved prescribing label's dosing schedule against the quantity requested. Confirm that the prescription precisely matches the label. 4. Submit a corrected prior authorization if the denial was administrative, or proceed to formal internal appeal if Humana maintains the restriction.

## Documentation to Gather

• Diagnosis confirmation: chart note establishing the indication (migraine diagnosis, frequency, and severity classification per your neurologist or headache specialist)
• Prescriber medical-necessity letter: a signed letter explaining why IV administration is appropriate for this specific patient, referencing the applicable American Headache Society or American Academy of Neurology guideline
• Infusion schedule documentation: the prescriber's intended dosing calendar, showing that the requested quantity matches the FDA-approved label interval
• Pharmacy or infusion-center records confirming prior doses received and the dates of administration

## Criteria-Mapping Structure

Copy each quantity-limit requirement listed in Humana's published policy. For each line, note the exact chart fact that satisfies it. For example: if the policy states that quantity is limited to one infusion per dosing interval, your supporting document should show the prescription interval, the label's stated interval, and confirmation they match. Leave no criterion unanswered — reviewers are trained to deny on any gap.